Wird geladen...
Risk for Gastrointestinal Perforation among Rheumatoid Arthritis Patients receiving Tofacitinib, Tocilizumab, or other Biologics
OBJECTIVE: To evaluate gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients receiving tofacitinib, tocilizumab or other biologics. METHODS: Using health plan data from 2006–2014, RA patients without prior GIP were identified. Those initiating tofacitinib or biologics were followe...
Gespeichert in:
| Veröffentlicht in: | Arthritis Rheumatol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5538140/ https://ncbi.nlm.nih.gov/pubmed/27213279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39761 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|